Introduction
As the management of symptomatic benign prostatic hyperplasia (BPH) has evolved, alpha-blockers have become the ®rst choice for medical therapy. They are a safe and effective noninvasive alternative to transurethral resection of the prostate (TURP), the traditional`goldstandard' BPH therapy. Alpha-blockers have been recommended as a ®rst-line therapy for BPH most recently by the International Consultation on BPH 1 and previously in the American Health Care Policy and Research (AHCPR) guidelines. 2 Factors that have led to the increasing popularity of alpha-blockade are patient preference for noninvasive treatment, 3 the signi®cant morbidities and high initial costs of TURP, 2 accumulating long-term data on the ef®cacy and safety of alpha-blockers, 4 ± 7 and the superior ef®cacy of alpha-blockers relative to ®nasteride. 8, 9 Finasteride, a 5-alpha-reductase inhibitor, is now considered an appropriate treatment option for the subset of BPH patients who have moderate or severe symptoms and very large sized prostates ( ! 40 g).
The primary goal of alpha-blocker therapy for BPH is to relieve lower urinary tract symptoms. These symptoms are believed to be caused mainly by bladder outlet obstruction secondary to enlargement of the prostate, to increased smooth muscle tone in the prostate, and to the detrusor response to prolonged voiding against a relatively obstructed outlet. Recently, however, this view has been challenged by evidence that bladder outlet obstruction is a weak predictor of symptom severity, and that prostate size is a very weak predictor of symptom severity and bladder outlet obstruction. 10 ± 12 Rationale for the use of alpha-blockers
The presumed mechanism of action of alpha-blockade in BPH is the relaxation of prostatic smooth muscle, which accounts for 40% of the area density of BPH tissue. 13 However, in light of the fact that men respond to alphablockers even in the absence of bladder outlet obstruction, 14 and that there is a weak correlation between the severity of lower urinary tract symptoms and bladder outlet obstruction, 15 it has been suggested that other mechanisms such as neurological pathways and sensory innervation of the prostate may be responsible for alphablocker ef®cacy. 11, 12 Only further elucidation of the pathophysiology of BPH will help to clarify the mechanism (or mechanisms) of action of alpha-blockers.
Alpha-blockers and uroselectivity
In the 20 years since Caine et al 16 reported that the prostatic capsule is responsive to alpha adrenergic stimulation, developments in alpha-blockers have centered on the facts that alpha-1 adrenoceptors predominate in the prostate 17 and are responsible for mediating smooth muscle tone. 18 These ®ndings in¯uenced the development of the alpha-blockers indicated for BPH, from the nonselective alpha-1 and alpha-2 antagonist phenoxybenzamine, to the short-acting selective alpha-1 antagonists alfuzosin, prazosin, and indoramin, to the long-acting selective alpha-1 antagonists doxazosin (Cardura 1 ), tamsulosin (Flomax 1 ), and terazosin (Hytrin 1 ).
In recent years, subtypes of the alpha-1 adrenoceptor have been characterized as alpha-1A, -1B, and -1D. 19 In the prostate, the alpha-1A subtype predominates, accounting for 70% of the total mRNA; the alpha-1B and alpha-1D subtypes account for the remaining 30%. 20 Outside of the prostate, the alpha-1A subtype has been found to be ubiquitous, 21 ± 23 the alpha-1B subtype is present in the vasculature and spleen, 24, 25 and the alpha-1D subtype is present in the vasculature and, as recent evidence suggests, in the bladder detrusor (accounting for 60 ± 70% of the total mRNA). 26 The predominance of the alpha-1A subtype in the prostate, and indications that this subtype may play a prime role in prostatic contraction, has led to research of alpha-1A-selective compounds and to the concept of uroselectivity' or prostate selectivity. In the past few years, there has been ongoing research for uroselective agents that act preferentially on prostate smooth muscle (alpha-1A) with little effect on the vasculature (alpha-1B and -1D) and central nervous system (CNS) in an attempt to improve clinical ef®cacy and curtail side effects.
Pharmacological selectivity is assessed in vitro by measuring the relative af®nities for the alpha-1A vs the -1B and -1D subtypes. Physiological or functional selectivity is assessed in vivo by measuring the relative phenylephrine-induced reductions in urethral pressure versus blood pressure: An ideal agent that demonstrates pharmacological and physiological selectivity would then clinically in BPH patients be expected to provide superior ef®cacy, minimal CNS ± and blood-pressure ± related side effects, and minimal hypotension. If the agent demonstrates optimal ef®cacy with minimal side effects, then this agent would be considered clinically uroselective.
The pharmacological and physiological selectivities of alfuzosin, doxazosin, tamsulosin, and terazosin have been reported in a number of published analyses. 27 ± 34 While some analyses indicate that tamsulosin is weakly selective for the alpha-1A subtype vs alpha-1B, 29, 33 others report that none of the four agents has subtype selectivity. 27, 28, 31 The consensus opinion of the Alpha-Blocker Committee at the 4th International Consultation on BPH was that none of these agents has any distinct selectivity for alpha-1-adrenoceptor subtypes nor for the prostate that could be indicative of clinical selectivity. 1 Regarding in vitro pharmacological selectivity, data ®rst reported by Kenny et al. 31 and cited in a recent review of alpha-blockers by Kirby 35 demonstrated that none of these alpha-blockers was selective for the alpha-1A subtype (Figure 1 ). Regarding in vivo physiological selectivity, Kenny et al 31 also reported that none of these alpha-blockers produced a greater reduction in urethral pressure than in blood pressure in the anesthetized dog model ( Figure 2) ; this was similar to tamsulosin data reported by Shibasaki et al. 34 Recently, Hancock et al 39 demonstrated in vivo in a conscious dog model that doxazosin, tamsulosin, and terazosin lowered mean arterial blood pressure in a dose-dependent manner. While an early report suggested that alfuzosin may preferentially reduce urethral pressure vs blood pressure, 32 there have been no subsequent studies to con®rm this.
In terms of uroselectivity, simply demonstrating pharmacological selectivity for only the alpha-1A receptor may not be suf®cient for achieving clinical uroselectivity (that is, optimizing ef®cacy and minimizing blood-pressure ± related effects). Firstly, alpha-1A receptors exist outside of the prostate and therefore may contribute to undesired nonurologic effects. Secondly, alpha-1B and alpha-1D subtypes may be as necessary as the alpha-1A subtype in achieving optimal ef®cacy; 11 these subtypes exist in the prostate, and their presence in other tissues may also contribute to ef®cacy. The alpha-1D receptor predominates in the bladder detrusor, and this may help confer optimal ef®cacy. Thirdly, an additional alpha-1 subtype, alpha-1L, has been de®ned in functional but not molecular studies, and has been proposed to mediate contraction of human lower urinary tract tissues. 36 Finally, selectivity observed pharmacologically and physiologically in preclinical in vitro and animal-model settings will not necessarily play out in humans. 21 In fact, Alpha-1-adrenoceptor blockade in BPH F Lowe to date, two compounds demonstrating a high degree of pharmacological selectivity in vitro for the alpha-1A subtype failed to produce suf®cient ef®cacy in men with BPH. 37 With these unanswered questions, de®nitive conclusions cannot be made about the particular alpha-1 subtypes that should and should not be blocked in the treatment of BPH. 1 
Ef®cacy and safety comparison of alphablockers
To date, only three comparative trials of the ef®cacy and safety of alpha-blockers have been published. In a doubleblind study, alfuzosin and tamsulosin produced comparable ef®cacy and safety. 38 In a pilot study of doxazosin (4 mg) and terazosin (5 mg) evaluating morning and evening dosing regimens, these two alpha-blockers produced comparable ef®cacy and safety, with evening dosing resulting in fewer side effects than morning dosing for both agents. 39 A single-blind study of tamsulosin and terazosin ef®cacy and safety has been published 40 but limitations of the study design undermine the conclusions and relevance of the comparison. These limitations include the lack of a double-blind study design, short study duration (8 weeks), low tamsulosin dose (0.2 mg), small numbers of patients (fewer than 40 in each group), and use of a Korean symptom scoring system.
Because of the paucity of head-to-head trials, in order to compare the ef®cacy and safety of currently available Alpha-1-adrenoceptor blockade in BPH F Lowe alpha-blockers, the results of published double-blind, placebo-controlled studies of alfuzosin, doxazosin, tamsulosin, and terazosin must be reviewed. Previous reviews have suggested that among these alpha-blockers there are no apparent differences in overall ef®cacy, and some quantitative but not qualitative differences in overall safety. 1,35,41 ± 44 This present analysis includes the most recent studies to date. There are some limitations in assessing the results of different studies together, for example differences in study design, study duration, number of patients, method of data analysis, etc.; however, this is the best approach available. To minimize potential biases in the following analysis, only placebocontrolled, double-blind trials published as full papers in peer-reviewed journals were selected. Trials published only as abstracts or supplements were excluded from this part of the review. All treatment effects reported in this analysisÐ both ef®cacy and safetyÐ are expressed in relation to placebo (drug effect). This review comprises 17 published reports representative of the literature on alfuzosin, doxazosin, tamsulosin, and terazosin, involving more than 8000 patients. 9,45 ± 60 One of these reports evaluated only safety data 57 and is therefore excluded from the ef®cacy sections below.
Effect on symptom score and peak¯ow rate
While a variety of ef®cacy endpoints (for example, changes in symptom score, peak¯ow rate, mean¯ow rate, residual volume, sexual function score, nocturia score, and proportion of patients responding) are reported in trials of medical therapy for BPH, the two most common primary ef®cacy endpoints are symptom score and peak¯ow rate; these were reported in the 16 trials and therefore allowed for a comparison of mean changes for the alpha-blockers in relation to placebo. For each of the 16 trials, Table 1 and Figures 3 and 4 summarize available data for baseline, mean change, and percent change in symptom score and peak¯ow rate for alfuzosin, doxazosin, tamsulosin, and terazosin in relation to placebo. To allow further comparisons among these trials, Table 1 also reports the number of randomized patients, number of weeks of therapy, symptom scoring system used, and common therapeutic doses used.
The trials used in this analysis employed a number of different symptom scoring systems: the International Prostate Scoring System (IPSS), the American Urological Association (AUA), the Boyarsky, and adaptations of these. Additionally, the baseline symptom scores can in¯uence the mean changes in symptom scores; larger reductions in symptom scores tend to occur with higher baselines, whereas smaller reductions occur with lower baselines. Table 1 and Figures 3 and 4 indicate overall that alfuzosin, doxazosin, tamsulosin, and terazosin provide a comparable range of improvement over placebo in symptom score (5 ± 31%) and peak¯ow rate (9 ± 24%). There is some suggestion that terazosin (9 ± 31%) may have a slightly better effect on symptom scores than doxazosin (5 ± 22%), tamsulosin (9 ± 20%), or alfuzosin (10 ± 13%). Regarding urinary¯ow, there is considerable overlap in the magnitude of improvement in peak¯ow rates of doxazosin (13 ± 23%), tamsulosin (6 ± 24%), and terazosin (8± 24%), while it appears that alfuzosin (12 ± 15%) might produce slightly less improvement.
Variances in the degree of the placebo effect can in¯uence the degree of drug-effect improvement. Firstly, in the Brawer et al study, 47 placebo produced an 11% Figure 3 Percent change in symptom score (SS) from baseline for alfuzosin, doxazosin, tamsulosin, and terazosin minus placebo.
9,45 ± 60
Alpha-1-adrenoceptor blockade in BPH F Lowe improvement in symptom score (which is lower than that reported in most other alpha-blocker studies), while terazosin produced a 42% improvement. Therefore, the low placebo effect in this study enhanced the resulting treatment effect (the difference between active drug and placebo); the symptom-score treatment effect of 31% is notably higher than in any of the other trials in Table 1 and Figures 3 and 4 . Secondly, in a study by Abrams et al, 46 patients receiving placebo had a 1% decrease in peak ow rate, which is lower than that reported in all other alpha-blocker studies, while tamsulosin produced a 23% increase. Therefore, the low placebo effect in this study produced an attributable drug effect on peak¯ow rate of 24%; this is markedly higher than that reported in the other four tamsulosin trials. 45, 49, 55, 58 There is con¯icting evidence as to whether tamsulosin 0.4 and 0.8 mg produce different magnitudes of symptom relief. While the 0.4 mg dose produced a 9 ± 14% improvement over placebo in symptom score in four studies, 45, 46, 49, 55 in one study the 0.8 mg produced a 20% improvement over placebo. 55 The recent Narayan study, however, suggests that there is no difference between the two dose levels in relieving symptoms. 58 This raises questions as to whether 0.4 mg or 0.8 mg is the optimal dose for symptom relief.
Proportion of patients responding
Beyond improvements in symptom score and peak¯ow rate, another measure of ef®cacy is the proportion of patients achieving a symptomatic response to treatment. In these 16 trials, the proportion of patients considered to be symptomatically responding to alpha-blocker therapy varied according to the de®nition of response. Some trials de®ned response as a ! 25% improvement in symptom score from baseline, 45, 49, 55, 58 while others used more stringent thresholds of ! 30%, 51,56 ! 35%, 59 or ! 50%. 47 One trial de®ned response as a successive range of improvement in symptom score from baseline of ! 10% up through ! 50%. 60 In other studies, response was de®ned subjectively by the patient or investigator. 46, 50, 54, 58 Three studies did not de®ne or report symptomatic response. 9, 52, 53 Because of the varying de®nitions of symptomatic response used in these 16 studies, it is impossible to conclude that one agent produces better responder rates than another agent. Overall, however, while there is no clear de®nition of responder, a markedly greater proportion of alpha-blocker patients (approximately 10 ± 30% greater) than placebo patients achieved a symptomatic response in these studies by either their own or their investigator's de®nition.
Long-term ef®cacy
BPH is a chronic disease; therefore, long-term data on alpha-blockers are needed to establish their durability. While there are no double-blind, placebo-controlled trials of alpha-blockers longer than 1 y, open-label studies have demonstrated the ef®cacy of these agents in BPH for 14 months up to 54 months. The longest-term alpha-blocker data have been published on terazosin and doxazosin. Terazosin has been shown to improve Boyarsky symptom scores 38 ± 51% (4.0 ± 5.4 units) from baseline (10.5 units) and peak¯ow rates 23 ± 40% (2.3 ± 4.0 mLas) from baseline (10.0 mLas) for up to 42 months of treatment (n 494 at Figure 4 Percent change in peak¯ow rate (PFR) from baseline for alfuzosin, doxazosin, tamsulosin, and terazosin minus placebo.
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Alpha-1-adrenoceptor blockade in BPH F Lowe entry; n 47 at 42 months). 5 Similar results have been reported in an extension of these terazosin data to 54 months (n 140 at 48 months; n 54 at 54 months). 61 Doxazosin has been shown to improve AUA and modi®ed Boyarsky symptom scores for severity and bothersomeness 14 ± 31% from baseline and peak¯ow rates 19% (1.9 mLas) from baseline (10.0 mLas) for up to 48 months (n 450 at entry; n 28 at 48 months). 6 Tamsulosin has been shown to improve Boyarsky symptom scores 36% (3.4 units) from baseline (9.4 units) and peak¯ow rates 13.7% (1.4 mLas) from baseline (10.2 mLas) for up to 14 months (n 240 at entry; n 181 at 14 months). 7 A preliminary report has indicated that tamsulosin maintains improved symptom scores and¯ow rates for up to 36 months. 62 Alfuzosin has been shown to improve Boyarsky symptom scores 40% (3.5 units) from baseline (8.7 units) for up to 24 months (n 50) and¯ow rates 7% (1.0 mLas) from baseline (13.6 mLas) for up to 12 months (n 46); alfuzosin, however, failed to maintain improvements in¯ow at 24 months (n 20), when¯ow rates decreased À6% (À0.9 mLas) from baseline (15.0 mLas). 4 Despite these studies, the long-term durability of these agents is still unknown and uncertain. It should be noted that the results of open-label studies may be somewhat enhanced because responding patients are included in the results and those withdrawing are not.
Safety
While there are differences in the incidence rates of speci®c side effects among alfuzosin, doxazosin, tamsulosin, and terazosin, the overall side-effect pro®les of these agents have been characterized as`very similar' by the Alpha-Blocker Committee at the 4th International Consultation on BPH. 1 Seventeen double-blind, placebocontrolled trials of these four agents are reviewed herein. Table 2 reports the incidence of selected side effects in these trials for each agent and placebo, as well as the respective attributable risks. There are many variables that can in¯uence the incidence of side effects: the de®nition of side effects, how actively the investigators elicited side effects, the degree of bother needed to register a particular side effect, the registering of transient side effects, the titration regimen, and the length of time patients were exposed to active drug. The incidence of side effects for the alpha-blockers must be judged against the respective placebo control arms to assess the attributable risk of the drugs.
The data in Table 2 suggests that the overall side-effect pro®les of doxazosin, tamsulosin, and terazosin are similar. Speci®c side effects that are notably higher than placebo are dizziness, asthenia, and headache with doxazosin; abnormal ejaculation, rhinitis, and dizziness with tamsulosin; and dizziness, postural hypotension, and asthenia with terazosin. While alfuzosin appears to be associated with lower rates of these side effects than the other agents, alfuzosin has not been as extensively investigated in double-blind, placebo-controlled trials. Table 2 is based on six such trials of terazosin, ®ve of tamsulosin, four of doxazosin, and two of alfuzosin. The terazosin trials investigated a greater number of randomized patients (n 4506) than the trials of tamsulosin (n 2488), alfuzosin (n 908), and doxazosin (n 785). (These n values represent the total number of randomized patients in trials listed for each agent in Table 2 . The total number for terazosin excludes patients from the McKiernan and Lowe survey 57 who are represented in three other terazosin studies). 47, 56, 59 Study durations were generally longer in terazosin studies (8 ± 52 weeks) than in trials of alfuzosin (12 ± 26 weeks), doxazosin (9 ± 16 weeks), and tamsulosin (4 ± 13 weeks).
Although the overall side-effect pro®les of alpha-blockers are similar, there are marked differences in the incidence of speci®c side effects among studies of the same drug. For example, for doxazosin, two separate studies report that the attributable risk of headache is 8% 52 and 0%. 53 For terazosin, two separate studies report that the attributable risk of dizziness is 19% 9 and 5.3%. 57 For tamsulosin, two separate studies report that the attributable risk of abnormal ejaculation is 10% 58 and 0%. 46 Also, there is a marked difference in the incidence of side effects reported in the two US tamsulosin trials 55, 58 vs the three European tamsulosin trials. 45, 46, 49 It is uncertain whether this is due to cultural differences, to the methodologies of the reporting of side effects, or to other factors.
The development of slow-release alpha-blocker formulations might affect the incidence of side effects. Doxazosin and terazosin are currently available as standardrelease formulations; for these agents, bedtime dosing and judicious stepwise titration of dose levels tend to minimize hypotensive side effects. 63 Alfuzosin and tamsulosin are sustained-or modi®ed-release formulations that allow for a gradual onset of action to help minimize hypotensive side effects. A slow-release formulation of doxazosin has now been developed, and initial reports suggest that it improves the side effect pro®le vs standard doxazosin. 64 Attributable drug effects (vs placebo) for discontinuation due to side effects in Table 2 suggest that doxazosin (5.8 ± 11.9%) and terazosin (2.5 ± 6.1%) may be associated with somewhat higher withdrawal rates than tamsulosin (0 ± 3%) and alfuzosin (0 ± 2%). Unfortunately, discontinuation data were not available for all 17 studies. One doxazosin 50 and one tamsulosin publication 55 each did not report these rates. While there may be slight differences in the side-effect pro®les of the four agents, from these data it can be concluded that alpha-blocker therapy is well tolerated, and that the majority of side effects with alpha-blockers are mild to moderate, seldom causing a patient to prematurely discontinue therapy.
Most of these 17 trials did not report side effects by dose level, so it is impossible to conclude from these data whether side effects increase with increased doses. Two tamsulosin trials 55, 58 and one terazosin trial 56 did list side effects by dose level. In these three studies, the only clearly dose-related side effect was abnormal ejaculation in the tamsulosin trials (6 ± 10% at 0.4 mg vs 17 ± 18% at 0.8 mg). A recent doxazosin report indicated that the incidence of side effects at 4 mg and 8 mg is similar. 65 
Long-term safety
Data on the long-term safety of alpha-blockers in BPH has been obtained only in open-label studies for 12 ± 54 months' duration. In general, the side effects with the highest incidence in short-term placebo-controlled studies (see Table 2 ) were also the most common in these longterm studies. In a 42-month study of terazosin 5 that has now been extended to 54 months, 61 and in a 48-month study of doxazosin, 6 the side effects with the highest incidence were dizziness, asthenia, headache, and somnolence. In a 14-month study of tamsulosin, 7 the side effects with the highest incidence were abnormal ejaculation, dizziness, headache, and postural hypotension. In a 24 ± 30-month study of alfuzosin, the side effects with the highest incidence were dizziness, headache, and malaisea postural hypotension. 4 
Safety in the elderly
There are concerns that the hemodynamically active alpha-blockers may cause elderly BPH patients to be at increased risk of dizziness or hypotension-related side effects. However, accumulating evidence to date suggests that alpha-blockade with doxazosin, tamsulosin, or terazosin is equally well tolerated in both older and younger BPH patients. 66 ± 70 Blood-pressure effects Alpha-blockers were originally developed for the treatment of hypertension and are now well established as safe and effective, although usually not as ®rst-line antihypertensive therapy. 71 In BPH patients, alpha-blockers have been shown to bene®cially reduce blood pressure in men with hypertension, but produce little or no reduction in normotensive patients. 55,72 ± 75 Evidence indicates that it is safe to co-administer alpha-blockade for BPH with preexisting antihypertensive treatment. The addition of The number of patients randomized to terazosin or placebo was 610; the other 619 patients were randomized to ®nasteride or combination therapy (terazosin plus ®nasteride). NR not reported or not available.
Alpha-1-adrenoceptor blockade in BPH F Lowe doxazosin or terazosin to pre-existing antihypertensive treatment has been shown to produce a bene®cial and safe reduction in blood pressure in noncontrolled hypertensive patients while producing little or no reduction in blood pressure in pharmacologically normotensive patients. 73, 75, 76 While some studies have suggested that tamsulosin produces a minimal effect on blood pressure in BPH patients, 45, 46 data from other studies suggest that tamsulosin may produce some reductions in men who have elevated blood pressure. In men with elevated blood pressure at baseline, tamsulosin's effect on supine diastolic blood pressure (mmHg) was À9.1 (101.6 baseline, 0.4 mg), 49 À8.1 (101.2, 0.4 mg), 38 À7.2 and À8.5 mmHg (baselines not reported, 0.4 and 0.8 mg), 55 and À6.6 (89.4, 0.2 mg). 40 While the blood-pressure changes for tamsulosin were not different from placebo in two of these studies, 49, 55 the magnitude of the changes (range À6.6 to À9.1 mmHg) approaches that reported for doxazosin 72 and terazosin 73 in hypertensive men with BPH (range À10.0 to À11.5 mmHg). Additionally, in two comparative trials of the blood-pressure effects of tamsulosin versus doxazosin 77 and vs terazosin, 78 tamsulosin was similar to the comparative agents. The latter study indicated that tamsulosin was associated with a lower level of nocturnal orthostatic hypotension.
Dose ranges and cost
In light of the fact that there are no marked differences in overall ef®cacy and safety among current alpha-blockers, for the practicing clinician the considerations of ease of administration and cost become important.
Tamsulosin and alfuzosin do not need to be titrated; therefore, the therapeutic dose may be reached on the ®rst day of therapy. Tamsulosin is available as a once-daily 0.4 mg dose. In the US, if a patient fails to achieve a suf®cient clinical response after a trial of tamsulosin 0.4 mg, the dose may be doubled to 0.8 mg (two 0.4 mg doses). Alfuzosin, which is only available outside of the US, is administered at a dose of 7.5 ± 10 mg per day in three divided doses. Recently a sustained-release (SR) formulation of alfuzosin, 5 mg administered twice daily, has been developed. Doxazosin (1 ± 8 mg) and terazosin (1 ± 10 mg) are available in escalating once-daily doses in both the US and in Europe. A clinical bene®t of doxazosin and terazosin therapy is that a wider range of therapeutic doses is available, whereby the dose can be increased until the optimal therapeutic response is achieved, or reduced if necessary to balance effectiveness with optimal tolerability for individual patients. BPH symptom severity varies from patient to patient, and thus one dose level of tamsulosin may not provide adequate symptomatic relief for many patients.
In the US, monthly (30 d) costs of these alpha-blockers at common therapeutic doses are as follows: doxazosin 4 and 8 mg, $31 and $32; tamsulosin 0.4 and 0.8 mg, $39 and $78; and terazosin 5 and 10 mg $46 and $46. 79 (Alfuzosin is not available in the US). Increasing the dose with doxazosin and terazosin does not increase the cost, whereas increasing the dose with tamsulosin doubles its cost. At the lowest common therapeutic doses, doxazosin and tamsulosin are less expensive than terazosin; at the highest doses, tamsulosin is the most expensive.
Conclusions
This present review indicates that, based on the results of 17 placebo-controlled, double-blind trials, there are no dramatic differences in the overall ef®cacy and safety of currently available alpha-blocking agents. While the data suggest that terazosin may provide some minor advantage in symptom relief over the other agents, and that there are some differences in the incidence of speci®c side effects, only a properly conducted, double-blind, comparative trial will reveal meaningful differences between agents. Such a trial must also include a placebo arm to properly elicit the degree of drug effects. Until such headto-head trials are conducted, clinicians need to determine, with each individual patient, what clinical features of a particular agent are best suited for the patient. Besides ef®cacy, safety, blood-pressure effects, therapeutic dose range, and cost, other considerations of alpha-blockers should include their effects on plasma lipids, 80 apoptosis, 81, 82 erectile function, 83, 84 and prostatitis. 85 In the future, the development of a true subtypeselective alpha-1 antagonist may lead to signi®cant advances in the medical treatment of BPH. It remains to be seen whether a subtype-selective agent will be able to reduce side effects while maintaining ef®cacy.
